Disseminated primary cutaneous marginal zone lymphoma (PCMZL) involves widespread cutaneous involvement across multiple skin sites. This presentation is managed differently from localized disease, and the clinical goal is achieving a complete response of the cutaneous lymphoma.
In disseminated PCMZL, the extent of skin involvement across multiple sites places patients outside the scope of purely local treatment strategies. Evidence supports the use of systemic therapy in this setting — including an intravenous anti-CD20 monoclonal antibody — reflecting the need for approaches that can address widespread disease.
Current evidence for disseminated PCMZL supports systemic treatment approaches, including an intravenous monoclonal antibody option. Additional systemic and palliative strategies also have defined roles in this setting. The complete structured protocol — covering all options, their sequencing, and any relevant clinical criteria — is available via the link below.
Full regimen details are not shown here.
Treatment goal: Complete response of the cutaneous lymphoma.
DOI: 10.3390/cancers12061497
View source ↗